Putnam Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

Putnam Investments’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-42,632	Closed	-$300K	–	1145
2023 Q2	$300K	Buy	42,632 +3,153	+8%	+$25.3K	﹤0.01%	1083
2023 Q1	$329K	Sell	39,479 -1,654	-4%	-$15.9K	﹤0.01%	1068
2022 Q4	$472K	Sell	41,133 -22	-0.1%	-$274	﹤0.01%	941
2022 Q3	$518K	Sell	41,155 -748	-2%	-$9.63K	﹤0.01%	933
2022 Q2	$443K	Sell	41,903 -518	-1%	-$5.34K	﹤0.01%	968
2022 Q1	$690K	Sell	42,421 -3,025	-7%	-$48.5K	﹤0.01%	941
2021 Q4	$629K	Buy	+45,446	New	+$601K	﹤0.01%	916
2016 Q1	–	Sell	-199,100	Closed	-$2.06M	–	1405
2015 Q4	$2.06M	Hold	199,100	–	–	﹤0.01%	967
2015 Q3	$2.27M	Hold	199,100	–	–	0.01%	953
2015 Q2	$2.97M	Sell	199,100 -2,130	-1%	-$24.2K	0.01%	926
2015 Q1	$1.82M	Buy	+201,230	New	+$2.08M	﹤0.01%	1074

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Putnam Investments's BCRX Position: Q3 2023 in Review

Putnam Investments sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2023, closing a stake of 42,632 shares — an estimated $300K sold.

Putnam Investments first reported a position in BCRX in Q1 2015 and held it in 11 quarters. The position peaked at $2.97M in Q2 2015. 233 funds tracked by Wall St. Rank hold BCRX as of Q3 2023.

Putnam Investments reported no remaining BioCryst Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Putnam Investments sold 42,632 BioCryst Pharmaceuticals shares in Q3 2023, an estimated $300K.
Putnam Investments first reported a position in BioCryst Pharmaceuticals in Q1 2015 and held it in 11 quarters.
Putnam Investments's BioCryst Pharmaceuticals position peaked at $2.97M in Q2 2015.
233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2023.

Based on Putnam Investments's 13F filing for Q3 2023, filed 14 Nov 2023.